Atıf İçin Kopyala
Hermans L. E., Svicher V., Pas S. D., Salpini R., Alvarez M., Ben Ari Z., ...Daha Fazla
JOURNAL OF INFECTIOUS DISEASES, cilt.213, sa.1, ss.39-48, 2016 (SCI-Expanded)
-
Yayın Türü:
Makale / Tam Makale
-
Cilt numarası:
213
Sayı:
1
-
Basım Tarihi:
2016
-
Doi Numarası:
10.1093/infdis/jiv363
-
Dergi Adı:
JOURNAL OF INFECTIOUS DISEASES
-
Derginin Tarandığı İndeksler:
Science Citation Index Expanded (SCI-EXPANDED), Scopus
-
Sayfa Sayıları:
ss.39-48
-
Anahtar Kelimeler:
antiviral drug resistance, genotypic resistance testing, hepatitis B virus, nucleos(t)ide analogs, COST-EFFECTIVENESS, REDUCED ANTIGENICITY, LAMIVUDINE TREATMENT, POLYMERASE GENE, PRIOR EXPOSURE, ENTECAVIR, MUTATIONS, TENOFOVIR, HBV, CONSEQUENCE
-
Dokuz Eylül Üniversitesi Adresli:
Hayır
Özet
European guidelines recommend treatment of chronic hepatitis B virus infection (CHB) with the nucleos(t)ide analogs (NAs) entecavir or tenofovir. However, many European CHB patients have been exposed to other NAs, which are associated with therapy failure and resistance. The CAPRE study was performed to gain insight in prevalence and characteristics of NA resistance in Europe.